Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
äŒæ¥ã³ãŒãCDXS
äŒç€ŸåCodexis Inc
äžå Žæ¥Apr 22, 2010
æé«çµå¶è²¬ä»»è
ãCEOãMoore (Alison)
åŸæ¥å¡æ°188
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Apr 22
æ¬ç€Ÿæåšå°200 Penobscot Dr
éœåžREDWOOD CITY
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·94063
é»è©±çªå·16504218100
ãŠã§ããµã€ãhttps://www.codexis.com/
äŒæ¥ã³ãŒãCDXS
äžå Žæ¥Apr 22, 2010
æé«çµå¶è²¬ä»»è
ãCEOãMoore (Alison)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã